Results - Announcements
Zim Laboratories Ltd share price fell 5.28% to Rs 134.6 after the company's net profit tumbled by 49% to Rs 2.05 crore, while revenue from operations edged up 11.97% to Rs 105.45 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, easing 5.14%. It has inched up 2.03% over last one week and gained upto 1.77% in last one month while the market capitalization of Zim Laboratories Ltd has eased by 1.50% and 20.07% in the same period respectively.
Profit before tax (PBT) of Zim Laboratories Ltd stood at Rs 2.74 crore in Q3 FY26, jumping 705.88% year-on-year, and nosediving by 50.81% quarter-on-quarter. EBITDA came in at Rs 3 crore, crashing by 15.63% YoY and expanding by 114.38% sequentially.
Total expenses saw a slight increase of 9.73% to Rs 106.55 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 40.84 crore, marginally falling by 6.80% YoY, while employee benefits expense was at Rs 19.59 crore, inching up 2.14% YoY.
For the TTM ended FY26, revenue from operations eased 1.22% to Rs 374.4 crore, while net profit tanked by 52.01% to Rs 5.84 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 3681% to Rs 18.63 crore, and PBT plunged by 54.41% to Rs 8.21 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 49.53 crore in FY26, as against Rs 41.15 crore in FY25.
Zim Laboratories Ltd jumped 83.58% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 7.38% during the same period.